Related Experiment Video

Updated: Oct 25, 2025

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

16.1K

CYB561D2 up-regulation activates STAT3 to induce immunosuppression and aggression in gliomas

Bangbao Tao1, Juanhong Shi2, Shuai Shuai3

  • 1Department of Neurosurgery, Xinhua Hospital, Shanghai Jiaotong University, School of Medicine, 1665 Kongjiang Road, Shanghai, 200092, China.

Journal of Translational Medicine
|August 10, 2021
PubMed
Abstract

Insights

This study reveals that CYB561D2 protein promotes glioma progression by activating STAT3, leading to immune suppression. Understanding this reactive oxygen species-tumor immunity crosstalk is key for glioma treatment.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Reactive oxygen species (ROS) balance is crucial for tumor cells.
  • Tumor cells utilize immune checkpoints to evade immune responses.
  • The interplay between ROS and immune checkpoints in gliomas is not well understood.

Purpose of the Study:

  • To investigate the role of CYB561D2, an antioxidant protein and glioma prognostic marker, in gliomas.
  • To elucidate the mechanisms by which CYB561D2 influences glioma progression and immune evasion.

Main Methods:

  • CYB561D2 expression analysis in clinical glioma samples and normal tissues.
  • In vitro and in vivo assays in glioma cell lines to assess CYB561D2 effects on tumor behavior and immunity.
  • Validation using open-access datasets.

Main Results:

  • CYB561D2 expression is elevated in gliomas, correlating with higher grade and poorer survival.
  • CYB561D2 activates STAT3, upregulating immunosuppressive genes (PD-L1, CCL2, TDO2) and promoting glioma cell growth, migration, and apoptosis resistance.
  • CYB561D2 overexpression reduces survival in vivo, an effect mitigated by STAT3 inhibition.

Conclusions:

  • CYB561D2 upregulation drives glioma aggression and immunosuppression through STAT3 activation.
  • CYB561D2 acts as a mediator in the crosstalk between reactive oxygen species and tumor immunity in gliomas.
Keywords:
CYB561D2GliomasImmune checkpointImmunosuppressionROSSTAT3

More Related Videos

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome07:23

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome

Published on: June 15, 2016

8.7K
Coculture Assays to Study Macrophage and Microglia Stimulation of Glioblastoma Invasion09:23

Coculture Assays to Study Macrophage and Microglia Stimulation of Glioblastoma Invasion

Published on: October 20, 2016

14.3K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.7K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
8.1K